Teva receives FDA approval of primary biliary cirrhosis drug

NORTH WALES, Pa. Teva Pharmaceuticals has introduced a generic version of a drug used to treat primary biliary cirrhosis, the generic drug maker announced Monday.

Teva has introduced ursodiol tablets in the 250 mg and 500 mg strengths. The tablets are respectively generic versions of Mont-Saint-Hilaire, Quebec-based Axcan Pharma’s Urso 250 and Urso Forte.

Urso 250 and Urso Forte had sales of $68.1 million for the 12 months that ended Sept. 30, 2007, according to Axcan’s latest available financial data.